BRITE-338733:从RECA抑制到癌症治疗
Tiyyaba Furqan1, Amira Bekdash1, Jisha Chalissery1
1Department of Biochemistry and Molecular Biology, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box: 15551, Al Ain, United Arab Emirates.
研究人员确定BRITE-338733作为RSC染色体重塑剂的新型抑制剂. 这种化合物由于其DNA结合和癌细胞细胞毒性,显示出作为抗癌治疗药物的潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 依赖ATP的染色体重塑剂通过改变染色体结构来调节细胞过程.
- 这些重塑剂的ATPase域是未充分探索的治疗点.
研究的目的:
- 通过计算识别和实验验证RSC染色体重塑器ATP水解活性的新型抑制剂.
- 针对ATP结合口袋和/或DNA相互作用部位.
主要方法:
- 使用对接研究进行计算选.
- 分子动力学模拟用于分析化合物行为.
- 使用ATP水解试验进行实验验证.
- 对DNA结合亲和力的评估.
- 在体外细胞毒性测定对乳腺癌细胞.
主要成果:
- 通过计算分析,BRITE-338733被确定为最有前途的抑制剂候选者.
- 实验测定证实了BRITE-338733.3的ATP水解的显著抑制.
- BRITE-338733证明了强大的与DNA的结合.
- 该化合物对乳腺癌细胞表现出细胞毒性.
结论:
- BRITE-338733是RSC染色体重塑剂的一个强有力的抑制剂.
- BRITE-338733的结合DNA的能力及其细胞毒性表明它有可能作为抗癌疗法.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Inhibition of Cdk Activity
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle
